Nerve testing devices maker NeuroMetrix (NURO) reported that it will exhibit its new NC-stat DPNCheck test at the Diabetic Foot Global Conference (DFCon), scheduled to be held in Los Angeles from March 15-17.
The NC-stat DPNCheck test has been designed for evaluating systemic neuropathies such as diabetic peripheral neuropathy (“DPN”). It is a modified version of NeuroMetrix’s popular NC-stat device for detecting DPN.
DPN, a common and serious complication of diabetes, affects roughly 60%-70% of diabetics and may lead to foot ulcers and amputations. Total annual health care costs associated with DPN in the U.S. are more than $11 billion.
The NC-stat DPNCheck measures the standard biomarkers for DPN such as sural nerve conduction velocity and amplitude. The device helps in the early detection, confirmation, and monitoring of DPN in a cost-effective manner at the point-of-care.
DFCon, which includes scientific and clinical lectures and specialized workshops, is among the leading annual conferences addressing the long-term implications of diabetes including DPN. It is focused on amputation prevention, diabetes management, and diabetic foot and wound care.
Medical professionals attending the diabetes workshop at the DFCon will get valuable exposure to a rapid, accurate and quantitative point-of-care approach to the early detection of DPN.
NeuroMetrix makes devices that help physicians detect and treat diseases and peripheral nerve injuries, and offer regional anesthesia and pain control. The company’s principal products are ADVANCE and NC-stat devices for nerve conduction study (“NCS”). NeuroMetrix competes with Medtronic (MDT) among others.
NeuroMetrix, in January 2012, reached an important commercial milestone for NC-stat DPNCheck as it booked the 100th order for the test. The company noted that roughly 200 physicians (including endocrinologists and podiatrists) in 100 medical practices are currently using the novel test to improve DPN management. NeuroMetrix hopes that the NC-stat DPNCheck will eventually achieve broad adoption across the U.S. and international markets.
More From Zacks.com